Chargement en cours...
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer
BACKGROUND: A phase 1/2a dose escalation study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) was conducted to determine maximum tolerated dose (MTD), recommended phase 2 dose, toxicities and efficacy in men with castrate-resistant prostate cancer (CRPC). METHODS: This open label phase 1/2a study ut...
Enregistré dans:
| Publié dans: | Invest New Drugs |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6844069/ https://ncbi.nlm.nih.gov/pubmed/26924129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0334-y |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|